Guizhou Shengjitang Pharmaceutical

Guizhou Shengjitang Pharmaceutical is a leading Chinese pharmaceutical enterprise primarily focused on the research, development, and manufacturing of treatments for chronic metabolic diseases. The company is a major player in the domestic diabetes market, offering a comprehensive portfolio of hypoglycemic medications including sustained-release formulations of metformin and gliclazide. In addition to its endocrinology focus, Shengjitang produces a variety of cardiovascular, digestive, and traditional Chinese medicine products. The company operates as the core pharmaceutical subsidiary of the Shanghai-listed Guizhou Shengjitang Co., Ltd. Its manufacturing facilities are GMP-certified, supporting large-scale production of oral solid dosages. Shengjitang continues to expand its pipeline through the development of generic versions of high-demand drugs like vildagliptin and dapagliflozin.